Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988364 | 0.92 | MAPT (0.53) | KMT2AMEN1CTDSP1MAPTGAA | |
| SCHEMBL8592402 | 0.87 | KMT2A (0.54) | KMT2AMEN1CTDSP1MAPTGAA | |
| SCHEMBL4769269 | 0.87 | KMT2A (0.50) | KMT2AMEN1CTDSP1MAPTGAA | |
| SCHEMBL4132271 | 0.86 | KMT2A (0.60) | KMT2AMEN1CTDSP1MAPTGAA | |
| SCHEMBL8591919 | 0.85 | MAPT (0.57) | KMT2AMEN1CTDSP1MAPTGAA | |
| SCHEMBL4109631 | 0.83 | KMT2A (0.66) | KMT2AMEN1MAPTGAAMAPK1 | |
| SCHEMBL8591021 | 0.80 | KMT2A (0.62) | KMT2AMEN1MAPTGAAMAPK1 | |
| SCHEMBL180229 | 0.78 | KMT2A (0.75) | KMT2AMEN1CTDSP1MAPTGAA | |
| SCHEMBL180228 | 0.78 | KMT2A (0.75) | KMT2AMEN1CTDSP1MAPTGAA | |
| Sivifene SCHEMBL18821 | 0.78 | KMT2A (0.72) | KMT2AMEN1MAPTGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2023-12-12 | — | — | US | claimed |
| WO-2024123585-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11892453-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2024-02-06 | — | — | US | disclosed |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2023-12-12 | — | — | US | disclosed |
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4161522-A1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | Merck Sharp & Dohme LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11596642-B2 | Therapeutic treatment of breast cancer based on c-MAF status | INBIOMOTION S.L. (ES) | 2023-03-07 | — | — | US | disclosed |
| EP-4076452-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20210388452-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | INBIOMOTION S.L. (ES) | 2021-12-16 | — | — | US | disclosed |
| EP-2310384-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010127754-A1 | 3-([1,2,3]TRIAZOLE-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATES | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
| EP-2247185-A2 | TYROSINE KINASE INHIBITORS | Tiger Pharmatech (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010114780-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010005841-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009111354-A2 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1888053-A2 | CONJUGATED AROMATIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | Dekk-Tec, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006130552-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006119284-A2 | CONJUGATED AROMATIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | DEKK-TEC, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2005118584-A2 | SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11892453-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, MAFK, ACP3 | KMT2A 975/4885MEN1 479/4885CTDSP1 918/4885 |
| US-20210388452-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | MAFG, ACP3, MAFK | KMT2A 986/4885MEN1 484/4885CTDSP1 1035/4885 |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, ACP3, MAFK | KMT2A 986/4885MEN1 484/4885CTDSP1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.